Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Publication year range
1.
BMC Anesthesiol ; 23(1): 140, 2023 04 27.
Article in English | MEDLINE | ID: mdl-37106321

ABSTRACT

BACKGROUND: The optimal time to intubate patients with SARS-CoV-2 pneumonia has not been adequately determined. While the use of non-invasive respiratory support before invasive mechanical ventilation might cause patient-self-induced lung injury and worsen the prognosis, non-invasive ventilation (NIV) is frequently used to avoid intubation of patients with acute respiratory failure (ARF). We hypothesized that delayed intubation is associated with a high risk of mortality in COVID-19 patients. METHODS: This is a secondary analysis of prospectively collected data from adult patients with ARF due to COVID-19 admitted to 73 intensive care units (ICUs) between February 2020 and March 2021. Intubation was classified according to the timing of intubation. To assess the relationship between early versus late intubation and mortality, we excluded patients with ICU length of stay (LOS) < 7 days to avoid the immortal time bias and we did a propensity score and a cox regression analysis. RESULTS: We included 4,198 patients [median age, 63 (54‒71) years; 71% male; median SOFA (Sequential Organ Failure Assessment) score, 4 (3‒7); median APACHE (Acute Physiology and Chronic Health Evaluation) score, 13 (10‒18)], and median PaO2/FiO2 (arterial oxygen pressure/ inspired oxygen fraction), 131 (100‒190)]; intubation was considered very early in 2024 (48%) patients, early in 928 (22%), and late in 441 (10%). ICU mortality was 30% and median ICU stay was 14 (7‒28) days. Mortality was higher in the "late group" than in the "early group" (37 vs. 32%, p < 0.05). The implementation of an early intubation approach was found to be an independent protective risk factor for mortality (HR 0.6; 95%CI 0.5‒0.7). CONCLUSIONS: Early intubation within the first 24 h of ICU admission in patients with COVID-19 pneumonia was found to be an independent protective risk factor of mortality. TRIAL REGISTRATION: The study was registered at Clinical-Trials.gov (NCT04948242) (01/07/2021).


Subject(s)
COVID-19 , Pneumonia , Respiratory Distress Syndrome , Adult , Female , Humans , Male , Middle Aged , COVID-19/therapy , Critical Illness/therapy , Hospital Mortality , Intensive Care Units , Intubation, Intratracheal , Oxygen , Respiration, Artificial , Retrospective Studies , SARS-CoV-2
2.
Med Intensiva ; 33(1): 40-9, 2009.
Article in Spanish | MEDLINE | ID: mdl-19232208

ABSTRACT

Spain has a rate of 34.4 donors per million population, making it the country with the highest rate of organ donation all over the world. In spite of these values, need of lungs for transplantation is always greater than the number of organs obtained. The adrenergic storming produced during brain herniation and the initiation of a brain death condition entail a series of pathophysiological alterations that can endanger the lung viability. In this paper, we review the evaluation of lung donor and its maintenance. In all the potential lung donors, the Apnea Test with CPAP should be done and the criteria for the donation of the lung under ideal conditions and with expanded criteria lung donors are reviewed. The protocol of aggressive maintenance including a protective ventilation strategy, restricted fluid intake, use of prophylactic antibiotics, corticosteroids and the systematic use of measures aimed at avoiding alveolar collapse together with maneuvers aimed at achieving better lung recruitment can improve the management of the lung donor and obtain a greater number of organs for transplantation.


Subject(s)
Lung Transplantation , Lung/physiopathology , Tissue Donors , Tissue and Organ Harvesting/methods , Adolescent , Adult , Aged , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Apnea , Brain Death/diagnosis , Brain Death/physiopathology , Continuous Positive Airway Pressure , Contraindications , Humans , Lung Transplantation/statistics & numerical data , Methylprednisolone/administration & dosage , Methylprednisolone/therapeutic use , Middle Aged , Organ Preservation/methods , Patient Selection , Respiration, Artificial , Tissue Donors/statistics & numerical data , Tissue Survival/drug effects , Tissue Survival/physiology , Tissue and Organ Harvesting/standards
SELECTION OF CITATIONS
SEARCH DETAIL
...